{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:09:13Z","timestamp":1790708953410,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41591-026-04487-3","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T09:04:09Z","timestamp":1782464649000},"page":"2639-2646","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cliramitug for depletion of cardiac amyloid transthyretin: long-term follow-up of the NI006-101 trial"],"prefix":"10.1038","volume":"32","author":[{"given":"Peter C.","family":"Kahr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"aus dem Siepen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lairez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwan","family":"Donal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Damy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnt V.","family":"Kristen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina C.","family":"Quarta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele F.","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Keppner-Witter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Herrmann-Keiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"Tichy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5246-4881","authenticated-orcid":false,"given":"Aubin","family":"Michalon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3898-3298","authenticated-orcid":false,"given":"Jan","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger M.","family":"Nitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Garcia-Pavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9705-4413","authenticated-orcid":false,"given":"Peter","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"4487_CR1","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia, P. et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 42, 1554\u20131568 (2021).","journal-title":"Eur. Heart J."},{"key":"4487_CR2","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg, F. L., Grogan, M., Hanna, M., Kelly, J. W. & Maurer, M. S. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J. Am. Coll. Cardiol. 73, 2872\u20132891 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"4487_CR3","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore, J. D. et al. A new staging system for cardiac transthyretin amyloidosis. Eur. Heart J. 39, 2799\u20132806 (2018).","journal-title":"Eur. Heart J."},{"key":"4487_CR4","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","volume":"68","author":"M Grogan","year":"2016","unstructured":"Grogan, M. et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J. Am. Coll. Cardiol. 68, 1014\u20131020 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"4487_CR5","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","volume":"2","author":"RK Cheng","year":"2020","unstructured":"Cheng, R. K. et al. Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis. JACC CardioOncol. 2, 414\u2013424 (2020).","journal-title":"JACC CardioOncol."},{"key":"4487_CR6","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","volume":"146","author":"A Ioannou","year":"2022","unstructured":"Ioannou, A. et al. Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years. Circulation 146, 1657\u20131670 (2022).","journal-title":"Circulation"},{"key":"4487_CR7","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/eurheartj\/ehae811","volume":"46","author":"E Gonzalez-Lopez","year":"2025","unstructured":"Gonzalez-Lopez, E., Maurer, M. S. & Garcia-Pavia, P. Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine. Eur. Heart J. 46, 999\u20131013 (2025).","journal-title":"Eur. Heart J."},{"key":"4487_CR8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/ejhf.2027","volume":"23","author":"T Damy","year":"2021","unstructured":"Damy, T. et al. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur. J. Heart Fail. 23, 277\u2013285 (2021).","journal-title":"Eur. J. Heart Fail."},{"key":"4487_CR9","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer, M. S. et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N. Engl. J. Med. 379, 1007\u20131016 (2018).","journal-title":"N. Engl. J. Med."},{"key":"4487_CR10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore, J. D. et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N. Engl. J. Med. 390, 132\u2013142 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4487_CR11","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.jacc.2024.11.042","volume":"85","author":"DP Judge","year":"2025","unstructured":"Judge, D. P. et al. Efficacy of acoramidis on all-cause mortality and cardiovascular hospitalization in transthyretin amyloid cardiomyopathy. J. Am. Coll. Cardiol. 85, 1003\u20131014 (2025).","journal-title":"J. Am. Coll. Cardiol."},{"key":"4487_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","volume":"392","author":"M Fontana","year":"2025","unstructured":"Fontana, M. et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N. Engl. J. Med. 392, 33\u201344 (2025).","journal-title":"N. Engl. J. Med."},{"key":"4487_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23274-x","volume":"12","author":"A Michalon","year":"2021","unstructured":"Michalon, A. et al. A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells. Nat. Commun. 12, 3142 (2021).","journal-title":"Nat. Commun."},{"key":"4487_CR14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2303765","volume":"389","author":"P Garcia-Pavia","year":"2023","unstructured":"Garcia-Pavia, P. et al. Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid. N. Engl. J. Med. 389, 239\u2013250 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4487_CR15","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","volume":"76","author":"JA Spertus","year":"2020","unstructured":"Spertus, J. A., Jones, P. G., Sandhu, A. T. & Arnold, S. V. Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review. J. Am. Coll. Cardiol. 76, 2379\u20132390 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"4487_CR16","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S0735-1097(24)02337-4","volume":"83","author":"R Yousuf","year":"2024","unstructured":"Yousuf, R. et al. Acoramidis may improve cardiac function and promote regression in transthyretin amyloid cardiomyopathy: data from the Attribute-Cm Cardiac Magnetic Resonance (Cmr) Substudy. JACC 83, 347\u2013347 (2024).","journal-title":"JACC"},{"key":"4487_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","volume":"14","author":"M Fontana","year":"2021","unstructured":"Fontana, M. et al. Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression. JACC Cardiovasc. Imaging 14, 189\u2013199 (2021).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"4487_CR18","doi-asserted-by":"publisher","first-page":"A4368781","DOI":"10.1161\/circ.152.suppl_3.4368781","volume":"152","author":"Y Razvi","year":"2025","unstructured":"Razvi, Y. et al. Abstract 4368781: Effects of vutrisiran on measures of cardiac structure, function and amyloid burden by cardiovascular magnetic resonance from the HELIOS-B Trial. Circulation 152, A4368781 (2025).","journal-title":"Circulation"},{"key":"4487_CR19","doi-asserted-by":"publisher","first-page":"4868","DOI":"10.3390\/jcm10214868","volume":"10","author":"S Oghina","year":"2021","unstructured":"Oghina, S. et al. Prognostic value of N-terminal pro-brain natriuretic peptide and high-sensitivity troponin T levels in the natural history of transthyretin amyloid cardiomyopathy and their evolution after tafamidis treatment. J. Clin. Med. 10, 4868 (2021).","journal-title":"J. Clin. Med."},{"key":"4487_CR20","doi-asserted-by":"publisher","unstructured":"Maurer, M. S. et al. Impact of vutrisiran on cardiac biomarkers in patients with transthyretin amyloidosis with cardiomyopathy from HELIOS-B. JACC https:\/\/doi.org\/10.1016\/j.jacc.2025.04.055 (2025).","DOI":"10.1016\/j.jacc.2025.04.055"},{"key":"4487_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/jamacardio.2023.4147","volume":"9","author":"SJ Shah","year":"2024","unstructured":"Shah, S. J. et al. Effect of tafamidis on cardiac function in patients with transthyretin amyloid cardiomyopathy: a post hoc analysis of the ATTR-ACT randomized clinical trial. JAMA Cardiol. 9, 25\u201334 (2024).","journal-title":"JAMA Cardiol."},{"key":"4487_CR22","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1038\/s41591-025-03851-z","volume":"31","author":"KS Jering","year":"2025","unstructured":"Jering, K. S. et al. Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial. Nat. Med. 31, 3560\u20133568 (2025).","journal-title":"Nat. Med."},{"key":"4487_CR23","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.ahj.2004.12.010","volume":"150","author":"J Spertus","year":"2005","unstructured":"Spertus, J. et al. Monitoring clinical changes in patients with heart failure: a comparison of methods. Am. Heart J. 150, 707\u2013715 (2005).","journal-title":"Am. Heart J."},{"key":"4487_CR24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/cpt.3455","volume":"117","author":"A Michalon","year":"2025","unstructured":"Michalon, A. et al. Prediction of cardiac ATTR depletion by NI006 (ALXN2220) using mechanistic PK\/PD modeling. Clin. Pharmacol. Ther. 117, 261\u2013269 (2025).","journal-title":"Clin. Pharmacol. Ther."},{"key":"4487_CR25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12350-019-01643-w","volume":"28","author":"C Gallini","year":"2021","unstructured":"Gallini, C. et al. Semi-quantitative indices of cardiac uptake in patients with suspected cardiac amyloidosis undergoing 99mTc-HMDP scintigraphy. J. Nucl. Cardiol. 28, 90\u201399 (2021).","journal-title":"J. Nucl. Cardiol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04487-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04487-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04487-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:02:19Z","timestamp":1784210539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04487-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4487"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04487-3","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.D. reports consulting fees and\/or research grants from Alnylam Pharmaceuticals, Alexion, Akcea, AstraZeneca, Bayer, BridgeBio, Ionis, Pfizer and Neurimmune F.S. reports speaking fees from Pfizer, Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Janssen, Bayer, Alexion and consulting fees from Pfizer, Alnylam Pharmaceuticals and Bayer. P.v.d.M. is supported by a grant from the European research Council (ERC CoG 101045236, DISSECT-HF). The University Medical Center Groningen, which employs P.v.d.M., received consultancy fees and\/or grants from Novartis, Pharmacosmos, Vifor Pharma, AstraZeneca, Neurimmune, Pfizer, Pharma Nord, BridgeBio, NovoNordisk and Ionis. O.L. reports speaking\/consulting fees from Alnylam, Amicus, AstraZeneca, Bayer, BMS, Pfizer, Sanofi-Genzyme. E.D. reports consulting and speaker fees from AstraZeneca, Pfizer and Alnylam. A.V.K. reports speaking fees from Bayer Vital, Pfizer, NovoNordisk, Attralus, Alexion and Alnylam Pharmaceuticals, and consulting fees from Bayer Vital, Pfizer, Neurimmune, NovoNordisk, Ionis, AstraZeneca and Intellia. M.F.M. and C.C.Q are employed by Alexion, AstraZeneca Rare Disease. J.G., R.M.N. and C.H. are employees and shareholders of Neurimmune AG. E.H.-K., S.K.-W., A.M. and P.C.K. are employees of Neurimmune AG. M.T. is a previous employee of Neurimmune AG. P.G.-P. reports speaking fees from Alnylam Pharmaceuticals, AstraZeneca, Bayer, BridgeBio, Intellia, Ionis Pharmaceuticals, NovoNordisk, and Pfizer, consulting fees from Alexion, Alnylam Pharmaceuticals, AstraZeneca, ATTRalus, Bayer, BridgeBio, Intellia, Ionis Pharmaceuticals, Life Molecular Imaging, Pfizer, Neurimmune, and NovoNordisk, and research\/educational support to his institution from Alnylam Pharmaceuticals, AstraZeneca, Bayer, BridgeBio, Intellia, NovoNordisk and Pfizer.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}